Mitomycin-C plus a 3-day continuous intravenous infusion of 5- fluorouracil: An inactive salvage regimen for platinum-resistant ovarian carcinoma

Bonnie Reichman; Maurie Markman; Thomas Hakes; Stephen Rubin; Walter Jones; John Curtin; Richard Barakat; Lois Almadrones; John L. Lewis; William Hoskins

doi:10.1006/gyno.1993.1159

Mitomycin-C plus a 3-day continuous intravenous infusion of 5- fluorouracil: An inactive salvage regimen for platinum-resistant ovarian carcinoma

Bonnie Reichman
, Maurie Markman
, Thomas Hakes
, Stephen Rubin
, Walter Jones
, John Curtin
, Richard Barakat
, Lois Almadrones
, John L. Lewis
, William Hoskins

Surgery

Division of Solid Tumor Oncology
Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

In a Phase II trial, patients with refractory ovarian cancer were given 10 mg/m² mitomycin-C iv every 8 weeks and 1000 mg/m²/day 5-fluorouracil for 3 consecutive days by continous intravenous infusion repeated every 4 weeks. Sixteen heavily pretreated patients with platinum-resistant disease were treated and no major responses were observed. Only 2 patients required subsequent dose reduction for myelotoxocity. No sign of gastrointestinal toxicity was seen. This regimen is inactive as salvage treatment for refractory ovarian cancer.

Original language	English
Pages (from-to)	30-33
Number of pages	4
Journal	Gynecologic Oncology
Volume	50
Issue number	1
DOIs	https://doi.org/10.1006/gyno.1993.1159
State	Published - Jul 1993

Keywords

Adult
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Drug Administration Schedule
Drug Resistance
Female
Fluorouracil/administration & dosage
Humans
Infusions, Intravenous
Middle Aged
Mitomycin/administration & dosage
Ovarian Neoplasms/therapy
Platinum/therapeutic use
Salvage Therapy

Access to Document

10.1006/gyno.1993.1159

Cite this

@article{fd0ce95864644304b53b94dc3bb51719,

title = "Mitomycin-C plus a 3-day continuous intravenous infusion of 5- fluorouracil: An inactive salvage regimen for platinum-resistant ovarian carcinoma",

abstract = "In a Phase II trial, patients with refractory ovarian cancer were given 10 mg/m2 mitomycin-C iv every 8 weeks and 1000 mg/m2/day 5-fluorouracil for 3 consecutive days by continous intravenous infusion repeated every 4 weeks. Sixteen heavily pretreated patients with platinum-resistant disease were treated and no major responses were observed. Only 2 patients required subsequent dose reduction for myelotoxocity. No sign of gastrointestinal toxicity was seen. This regimen is inactive as salvage treatment for refractory ovarian cancer.",

keywords = "Adult, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Drug Administration Schedule, Drug Resistance, Female, Fluorouracil/administration \& dosage, Humans, Infusions, Intravenous, Middle Aged, Mitomycin/administration \& dosage, Ovarian Neoplasms/therapy, Platinum/therapeutic use, Salvage Therapy",

author = "Bonnie Reichman and Maurie Markman and Thomas Hakes and Stephen Rubin and Walter Jones and John Curtin and Richard Barakat and Lois Almadrones and Lewis, \{John L.\} and William Hoskins",

year = "1993",

month = jul,

doi = "10.1006/gyno.1993.1159",

language = "English",

volume = "50",

pages = "30--33",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Mitomycin-C plus a 3-day continuous intravenous infusion of 5- fluorouracil

T2 - An inactive salvage regimen for platinum-resistant ovarian carcinoma

AU - Reichman, Bonnie

AU - Markman, Maurie

AU - Hakes, Thomas

AU - Rubin, Stephen

AU - Jones, Walter

AU - Curtin, John

AU - Barakat, Richard

AU - Almadrones, Lois

AU - Lewis, John L.

AU - Hoskins, William

PY - 1993/7

Y1 - 1993/7

N2 - In a Phase II trial, patients with refractory ovarian cancer were given 10 mg/m2 mitomycin-C iv every 8 weeks and 1000 mg/m2/day 5-fluorouracil for 3 consecutive days by continous intravenous infusion repeated every 4 weeks. Sixteen heavily pretreated patients with platinum-resistant disease were treated and no major responses were observed. Only 2 patients required subsequent dose reduction for myelotoxocity. No sign of gastrointestinal toxicity was seen. This regimen is inactive as salvage treatment for refractory ovarian cancer.

AB - In a Phase II trial, patients with refractory ovarian cancer were given 10 mg/m2 mitomycin-C iv every 8 weeks and 1000 mg/m2/day 5-fluorouracil for 3 consecutive days by continous intravenous infusion repeated every 4 weeks. Sixteen heavily pretreated patients with platinum-resistant disease were treated and no major responses were observed. Only 2 patients required subsequent dose reduction for myelotoxocity. No sign of gastrointestinal toxicity was seen. This regimen is inactive as salvage treatment for refractory ovarian cancer.

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Drug Administration Schedule

KW - Drug Resistance

KW - Female

KW - Fluorouracil/administration & dosage

KW - Humans

KW - Infusions, Intravenous

KW - Middle Aged

KW - Mitomycin/administration & dosage

KW - Ovarian Neoplasms/therapy

KW - Platinum/therapeutic use

KW - Salvage Therapy

UR - https://www.scopus.com/pages/publications/0027218276

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:A1993LT27700007&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1006/gyno.1993.1159

DO - 10.1006/gyno.1993.1159

M3 - Article

C2 - 8349161

SN - 0090-8258

VL - 50

SP - 30

EP - 33

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 1

ER -

Mitomycin-C plus a 3-day continuous intravenous infusion of 5- fluorouracil: An inactive salvage regimen for platinum-resistant ovarian carcinoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this